Interesting Images68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic PatientZhao, Liang MD∗; Gu, Jianwei MD†; Fu, Kaili MD∗; Lin, Qin MD, PhD∗; Chen, Haojun MD, PhD†Author Information From the Departments of ∗Radiation Oncology †Nuclear Medicine and Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Received for publication December 31, 2019; revision accepted February 8, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Haojun Chen, MD, PhD, Department of Nuclear Medicine and Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, 55 Zhenhai Rd, Xiamen 361003, China. E-mail: email@example.com. Clinical Nuclear Medicine: October 2020 - Volume 45 - Issue 10 - p e430-e432 doi: 10.1097/RLU.0000000000003015 Buy Metrics Abstract 68Ga-FAPI PET/CT was performed in a 56-year-old cirrhotic patient with multiple liver nodules, which were suspected of hepatocellular carcinoma by contrast-enhanced magnetic resonance but were not visualized by 18F-FDG PET/CT. Increased 68Ga-FAPI liver uptake was observed in this cirrhotic patient. However, the nodules had no pathological 68Ga-FAPI uptake and were clearly visualized due to the low activity compared with surrounding liver parenchyma. The 68Ga-FAPI PET/CT features, suggestive of benign nodules, have been later confirmed by histopathological examination. This case suggested that 68Ga-FAPI PET/CT may be useful in the differentiation between benign nodules and hepatocellular carcinoma in the patient with liver cirrhosis. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.